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Summary
To understand the T cell response to prostate cancer, we created transgenic mice that express a model antigen in a
prostate-restricted pattern and crossed these animals to TRAMP mice that develop spontaneous prostate cancer. Adop-
tive transfer of prostate-specific CD4 T cells shows that, in the absence of prostate cancer, the prostate gland is mostly
ignored. Tumorigenesis allows T cell recognition of the prostate gland—but this recognition is tolerogenic, resulting in
abortive proliferation and ultimately in hyporesponsiveness at the systemic level. Androgen ablation (the most common
treatment for metastatic prostate cancer) was able to mitigate this tolerance—allowing prostate-specific T cells to expand
and develop effector function after vaccination. These results suggest that immunotherapy for prostate cancer may be
most efficacious when administered after androgen ablation.S I G N I F I C A N C E
In 2004, approximately 30,000 men will die of metastatic prostate cancer. While androgen ablation has a high initial response rate,
most patients who develop progressive disease eventually die of cancer. To assess prostate/prostate cancer-specific immune
responses, we developed a transgenic mouse model that expresses a well-characterized antigen exclusively in the prostate gland
and in spontaneously arising prostate tumors. Using this transgenic model, we show that immunotherapy for prostate cancer may
be limited by the propensity for prostate-specific T cells to rapidly develop tolerance. Unexpectedly, we found that androgen
ablation mitigated T cell tolerance at a systemic level, suggesting that immunotherapy for prostate cancer may be augmented
when applied in conjunction with this common intervention.Introduction
One of the major obstacles to the development of vaccine stra-
tegies for treating cancer is that the T cell compartment often
develops tolerance to tumor antigens (Staveley-O'Carroll et al.,
1998; Morgan et al., 1998; Hu et al., 1993). This difficulty is
likely to be most pronounced for antigens that are shared be-
tween tumors and normal tissues, as the immune system will
have access to these antigens long before tumors develop. An-
tigens that are sequestered from the immune system might
have some advantage in this regard, remaining unrecognized
until tumorigenesis occurs. A potential example is the prostate
gland, which gives rise to prostate cancer—the most common
malignancy in American men (Jemal et al., 2003). The nonvital
nature of the prostate gland, coupled with the observation that
specialized prostate epithelial cells share antigens with pros-
tate tumors, makes prostate cancer an attractive target for im-
munotherapy. This concept was borne out by experiments that
showed vaccination using irradiated prostate tumor cells com-
bined with CTLA-4 blockade led to immune responses that
were restricted to both normal and malignant prostate tissues
(Hurwitz et al., 2000).CANCER CELL : MARCH 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INTo understand the immune response to the prostate gland
and investigate prostate cancer immunotherapy, we created
transgenic mice that express the model antigen influenza hem-
agglutinin under the control of the prostate-specific minimal rat
probasin promoter (Pro-HA) (Rennie et al., 1993). We found that
naive prostate-specific CD4 T cells are mostly ignorant of the
prostate gland, suggesting that, in the absence of tumorigene-
sis, prostate-specific tolerance might not be generated. When
Pro-HA mice were crossed with TRAMP mice that develop
spontaneous prostate cancer, naive T cells were able to recog-
nize the prostate gland. However, this recognition was tolero-
genic—leading to abortive proliferation, an absence of effector
cytokine production, and impaired responsiveness to vacci-
nation.
Androgen ablation is the most common therapy for prostate
cancer that cannot be treated with surgery or radiation (Den-
meade and Isaacs, 2002). In mice without prostate cancer, we
found that androgen ablation leads to a transient increase in T
cell recognition of the prostate gland, followed by a return to
baseline recognition levels. In mice with prostate cancer, a pro-
gressive decrease in T cell recognition of the prostate gland
was noted after androgen ablation. At the systemic level, thisC. DOI 10.1016/j.ccr.2005.01.027 239
A R T I C L Edecreased recognition was sufficient to abrogate CD4 T cell
tolerance and allow these cells to develop effector function in
response to vaccination. These data suggest that immunother-
apy approaches for prostate cancer may prove most effica-
cious when applied after androgen ablation.
Results
Generation and characterization of transgenic mice
expressing HA on prostate epithelia
To generate transgenic mice that express HA exclusively on
prostate epithelia, the minimal rat Probasin promoter (−426 to
+28 bp) (Greenberg et al., 1994, 1995; Rennie et al., 1993) was
used to drive HA expression. Since the prostate epithelia pro-
duce numerous proteins that are secreted into the prostatic
lumen and since many of these proteins are potential targets
for immunotherapy because they are also expressed on pros-
tate tumors, we engineered a secreted form of HA (HAs) that
was truncated to remove the cytoplasmic domain as well as
the C-terminal half of the transmembrane domain. The result-
ing HAs protein retains a Kd-restricted epitope located in the
N-terminal half of the transmembrane domain that is recog-
nized by clone 4 TCR transgenic CD8 cells (Morgan et al.,
1996), as well as an I-Ed-restricted epitope located in the extra-
cellular domain that is recognized by 6.5 TCR transgenic CD4
cells (Kirberg et al., 1994) (Figure 1A). To verify that the HAs
peptide is secreted rather than expressed on the plasma mem-Figure 1. The Pro-HA expression construct
A: The Pro-HA transgene, with the structure of
the secreted HA (HAs) protein shown above. A
map of the HA wt protein shows the locations of
the ER signal sequence (SS, amino acids 2–17),
the I-Ed epitope (amino acids 110–120, located
within the extracellular domain [ED]), the Kd epi-
tope (amino acids 542–550, located within the
trans-membrane domain [TM, amino acids 539–
564]), and the cytoplasmic domain (CD). The
structure of the HAs protein is shown by a thick
black line designating the portion of the wild-
type protein that has been retained.
B: Subcellular localization of HA wt and HAs pro-
teins. FACS histogram plots of P815 cells infected
with the indicated recombinant vaccinia (or
not infected as a background staining control
[C]) and stained for HA either directly (Surface)
or after membrane fixation and permeabiliza-
tion (Intracellular).
C: Immunoprecipitation of HA wt and HAs pro-
teins. COS-7 cells were transiently transfected
with expression plasmids encoding the HA wt or
HAs constructs, or the empty expression plasmid
(C). Forty-eight hours later, they were labeled
with [35S]methionine for 1 hr (pulse) and then
cultured an additional 3 hr with an excess of
cold methionine (chase). Following both the
pulse and chase periods, cell pellets (P) as well
as media supernatants (S) were harvested for
immunoprecipitation using the anti-HA mAb H-18.
Samples were analyzed by SDS-PAGE, with the
location of molecular weight standards shown
on the left, and the location of the HA proteins
marked by an arrow to the right of each autora-
diogram. Both short (S) as well as long (L) time
exposures of the chase autoradiogram are
shown.240brane, we employed two strategies. In the first, P815 cells were
infected with recombinant vaccinia viruses expressing either
the full-length or truncated HA sequence and subsequently an-
alyzed by FACS using the HA-specific mAb H-18 (Figure 1B).
Fixation and permeabilization prior to staining resulted in intra-
cellular detection of both the HA wt and HAs peptides (al-
though the HAs peptide was present at lower levels); however,
cells that were not fixed and permeabilized only exhibited sur-
face staining of the HA wt peptide. Thus, it appeared that the
HAs peptide was translated, but not expressed on the cell sur-
face. To verify that this lack of surface expression was the re-
sult of secretion, COS-7 cells were transiently transfected with
expression vectors containing the HA wt and HAs sequences,
metabolically labeled with 35S-methionine, and both solubilized
cell pellets and media supernatants were immunoprecipitated
with the H-18 mAb following either a 1 hr pulse or 3 hr chase
period (Figure 1C). Following the pulse, both the HA wt and
HAs peptides were immunoprecipitated from the cell pellet
fractions, but not from supernatants. The HAs (but not HA wt)
peptide was subsequently detected in the supernatant follow-
ing the chase period, confirming that it was secreted.
The Pro-HA expression cassette was microinjected into fer-
tilized B10.D2 embryos, and the founder line 9972 was estab-
lished and used in subsequent studies. Southern analysis indi-
cated the integration of a single intact transgene copy (data
not shown), and quantitative RT-PCR analysis demonstrated
prostate-specific HA expression (Figure 2A). Two approachesCANCER CELL : MARCH 2005
A R T I C L EFigure 2. Pro-HA transgenic mice express pros-
tate-restricted hemagglutinin
A: Quantitative RT-PCR was performed on the
indicated tissues of Pro-HA mice using HA-spe-
cific primers and probe. Relative expression is
shown normalized to C3-HA prostate (100),
which was used as a positive control for HA ex-
pression (Adler et al., 1998, 2000). Reactions
were run in triplicate and repeated two times.
B: Pro-HA mice express prostatic HA protein.
Prostate homogenates from the indicated mice
were injected into the footpads of NT recipients
that had received adoptive transfers of naive
6.5 clonotypic CD4 cells the previous day. Five
days later, single-cell suspensions prepared from
the draining popliteal LNs were analyzed by
FACS. Histogram plots of CD44 expression on
gated clonotypic CD4 cells are presented with
the mean fluorescence (MF) values shown to
the left of the dashed reference line. The data
shown is representative of several replicates.
C: Infiltration of primed clonotypic CD8 cells into
Pro-HA prostates. Pro-HA (right panel) and NT
(control, left panel) mice expressing the Thy1.2
congenic marker received adoptive transfers of
Thy1.1+ naive clone 4 clonotypic CD8 cells and
were simultaneously inoculated with vacc-HA
to prime the clonotypic CD8 cells. Two weeks
later, frozen sections of dorsal prostate lobes
were stained with an anti-Thy1.1 mAb (red stain)
and counterstained with hematoxylin. The sec-
tions shown are representative of several mice.
D: Thymic deletion of clonotypic CD4 cells does
not occur in Pro-HA transgenic mice. 6.5 TCR single transgenic, 6.5 × C3-HA and 6.5 × Pro-HA double transgenic mice were analyzed for clonotypic TCR
(i.e., 6.5) expression on CD4 single positive thymocytes and mature splenic CD4 cells. A dotted reference line indicates background 6.5 staining (deter-
mined from a NT control). Histogram plots are representative of multiple mice.were used to assess whether Pro-HA transgenic prostates ex-
press HA protein. First, Pro-HA prostate homogenates were in-
jected into the footpads of nontransgenic (NT) recipients that
had also received adoptive transfers of naive 6.5 clonotypic
CD4 cells. If the homogenates contain HA protein, the I-Ed-
restricted HA epitope should be presented by APCs in the
draining popliteal LNs, and the clonotypic CD4 cells should
lose their naive phenotype (Adler et al., 1998). Five days follow-
ing injection of Pro-HA prostate homogenate, the recovered
clonotypic CD4 cells exhibited increased expression levels of
the activation marker CD44 relative to control recipients. The
magnitude of CD44 expression induced by Pro-HA homoge-
nates was roughly comparable to homogenates from C3-HA
transgenic prostates (Figure 2B), which express HA in multiple
tissues including the prostate (Adler et al., 1998). To further
assess whether Pro-HA mice express sufficient levels of pros-
tatic HA to be recognized by HA-specific T cells in situ, Pro-
HA and NT (control) Thy1.2+ recipients received adoptive
transfers of naive Thy1.1+ HA-specific clonotypic CD8 T cells
and were simultaneously inoculated with a recombinant vac-
cinia virus expressing HA (vacc-HA) to prime the clonotypic
CD8 cells. Two weeks later, frozen sections prepared from dor-
sal prostate lobes were stained with anti-Thy1.1 to mark the
clonotypic CD8 cells (Figure 2C). In Pro-HA prostates, but not
in NT prostates, the primed clonotypic CD8 cells infiltrated the
prostatic ducts as evidenced by staining that colocalized with
the epithelium (the presumed site of transgene expression
[Greenberg et al., 1994, 1995]).CANCER CELL : MARCH 2005Prostatic HA is ignored by cognate naive CD4 cells
in Pro-HA mice
Some transgenes under the control of “tissue-specific” pro-
moters can be expressed at low levels in the thymus (Jolicoeur
et al., 1994). In fact, a number of “peripheral” proteins are ex-
pressed at low levels in thymus, suggesting that tolerance to
some peripheral antigens may be generated thymically (Joli-
coeur et al., 1994; Derbinski et al., 2001; Anderson et al., 2002).
To determine whether the Pro-HA transgene induces thymic
deletion of HA-specific T cells, we generated double trans-
genic mice that expressed both the 6.5 TCR and Pro-HA
transgenes (Figure 2D). Single transgenic 6.5 mice express
high levels of the clonotypic TCR on a large proportion of their
CD4 single positive thymocytes, as well as on mature splenic
CD4 cells. When the 6.5 mice were crossed with C3-HA trans-
genics that express HA in a number of tissues (including the
thymus [Adler et al., 1998]), the frequency of 6.5+ CD4 cells in
both the thymus and spleen were greatly reduced. In contrast,
thymic deletion of clonotypic CD4 cells did not occur in 6.5 ×
Pro-HA double transgenics (consistent with the lack of thymic
transgene mRNA expression [Figure 2A]). Given that the 6.5
clonotypic TCR has a relatively high affinity for the I-Ed-HA
peptide complex and is sensitive to the presence of thymic HA
(Jordan et al., 2001), this result suggests that a normal HA-
specific T cell repertoire is exported from the thymus of Pro-
HA transgenic mice. It is interesting that thymic deletion of HA-
specific T cells does not occur in Pro-HA mice, given that the
Probasin promoter driving SV40 T antigen expression in241
A R T I C L ETRAMP transgenic mice is expressed thymically and results in
thymic deletion of T antigen-specific T cells (Zheng et al.,
2002). Since the endogenous murine Probasin gene is also ex-
pressed at low levels in the thymus (Zheng et al., 2002), the
lack of deletion in Pro-HA mice might result from a fortuitous
integration site of the Pro-HA transgene that limits thymic
mRNA expression.
To assess whether mature naive CD4 cells recognize pros-
tatic HA in the periphery of Pro-HA mice, we performed adop-
tive transfer experiments using CFSE-labeled HA-specific clo-
notypic CD4 T cells (Figures 3A and 3B). As positive controlsFigure 3. Prostate tumorigenesis alters presenta-
tion of prostate-epithelial antigen
Age-matched (6-month-old) Thy1.2+ NT, C3-HA,
Pro-HA, TRAMP, Pro-HA x TRAMP, and vacc-HA-
infected NT (vacc-HA) recipients received
adoptive transfers of Thy1.1+ CFSE-labeled naive
clonotypic CD4 cells, which were recovered
from the prostate-draining periaortic LNs 6 days
later.
A: Representative proliferative responses (i.e.,
CFSE-dilutions) of clonotypic CD4 cells. The per-
centage of clonotypic CD4 cells (Thy1.1+ and
6.5+) exhibiting diluted CFSE fluorescence is
shown to the left of the dashed reference line.
B: Scatter plot showing the effect of tumorigen-
esis on clonotypic CD4 cell proliferation. The
percentage of CFSE-diluted clonotypic CD4
cells are shown for individual mice, with hori-
zontal lines designating the median values. p
values were calculated using an unpaired two-
tailed t test.
C: Representative histogram plots of IFN-γ stain-
ing, with the percentage of cytokine-positive
clonotypic CD4 cells, as well as the level of cy-
tokine expression on these positive cells (ex-
pressed as mean fluorescence [MF]) shown
above and below the reference bar, respec-
tively.242for antigen recognition, we used C3-HA recipients in which clo-
notypic CD4 cells undergo a vigorous proliferative response
prior to reaching a tolerant state, as well as NT recipients in-
fected with vacc-HA in which the clonotypic CD4 cells prolifer-
ate and develop Th1 effector function (Adler et al., 2000; Hig-
gins et al., 2002b). Six days post-transfer, clonotypic CD4 cells
recovered from the prostate-draining periaortic LNs of Pro-HA
recipients had not undergone significant division (i.e., CFSE di-
lution), nor had they divided in prostate-non-draining lymphoid
organs such as the spleen and the axillary and mesenteric LNs
(data not shown). Thus, the expression of prostatic HA (FiguresCANCER CELL : MARCH 2005
A R T I C L E2B and 2C) neither induces thymic deletion (Figure 2D), nor
peripheral recognition by mature CD4 cells (Figures 3A and 3B).
Prostate tumorigenesis leads to increased tolerogenic
recognition of prostatic HA in the prostate-draining LN
Prostatic HA might be ignored by cognate naive CD4 cells be-
cause under normal circumstances secreted HA is not directed
toward the bloodstream or draining lymphatics (Whitmore and
Gittes, 1977) and hence is unavailable to tolerogenic APCs
(Adler et al., 1998; Higgins et al., 2002b). Thus, we analyzed
HA-specific T cell responses in the setting of tumorigenesis,
where altered prostatic architecture and/or metastases might
allow HA to gain access to draining LNs. Pro-HA mice were
crossed to TRAMP transgenic mice that develop spontaneous
prostate tumors resulting from SV40 T antigen expression
driven under the control of the minimal rat Probasin promoter
(Greenberg et al., 1995). In these double transgenic mice, HA
and T antigen should be coexpressed during the transforma-
tion process since they are both under the control of an iden-
tical promoter. In contrast to Pro-HA and TRAMP single trans-
genic recipients in which adoptively transferred CFSE-labeled
naïve clonotypic CD4 cells remained undivided, a significant
fraction of these cells underwent division in Pro-HA × TRAMP
double transgenic recipients. Although the extent of prolifera-
tion was less in Pro-HA × TRAMP recipients than in C3-HA and
vacc-HA-infected NT control recipient groups, it was signifi-
cantly greater than in either Pro-HA or TRAMP single trans-
genic recipients (Figures 3A and 3B). This increased antigen
recognition appeared to be tolerogenic; the clonotypic CD4
cells that did divide only underwent a limited number of divi-
sions, and there was not an increased frequency of cells at
later relative to earlier divisions, suggesting that the divided
cells were prone to deletion.
To further assess the functional capacity of the divided clo-
notypic CD4 cells recovered from the prostate-draining LNs of
Pro-HA × TRAMP double transgenic recipients, we performed
intracellular IFN-γ staining following in vitro restimulation with
HA peptide-pulsed APCs (Figure 3C). Consistent with our pre-
vious observations (Higgins et al., 2002a, 2002b), clonotypic
CD4 cells primed in vacc-HA-infected NT recipients expressed
high levels of IFN-γ following in vitro restimulation, while coun-
terparts tolerized in C3-HA recipients did not. The divided clo-
notypic CD4 cells recovered from Pro-HA × TRAMP recipients
exhibited negligible intracellular IFN-γ expression, consistent
with a nonimmunogenic response. Furthermore, these cells did
not express IL-4 or IL-10, arguing against a Th2 or regulatory
response (data not shown).
Androgen ablation transiently increases immunological
recognition of a prostate-restricted antigen
Castration (i.e., androgen ablation) induces apoptotic degener-
ation of the prostate epithelia (Sugimura et al., 1986; Furuya et
al., 1995). Apoptotic cells can be cleared by phagocytic APCs,
a process that has been hypothesized to be a mechanism by
which tolerogenic APCs acquire parenchymal self-antigens
(Steinman et al., 2000; Liu et al., 2002). To assess whether an-
drogen-blockade-induced prostate epithelial degeneration in-
fluences the quantity or quality of antigen recognition in the
draining LNs, single transgenic Pro-HA recipients were
castrated prior to receiving CFSE-labeled naive clonotypic CD4
cells. Castration 1 day prior to adoptive transfer increased theCANCER CELL : MARCH 2005amount of clonotypic CD4 cell proliferation relative to intact
single transgenic Pro-HA recipients, albeit to a lesser degree
than did tumorigenesis (Figures 4A and 4B), and these divided
cells expressed negligible levels of IFN-γ following in vitro re-
stimulation (Figure 4C). When adoptive transfers were per-
formed 3 or 10 days following castration, the resulting CFSE-
dilution profiles approached those of intact Pro-HA recipients,
indicating that androgen ablation is only able to transiently
increase antigen recognition (presumably due to either loss of
HA-expressing prostate epithelia or to decreased androgen-
mediated HA expression). Similarly, when Pro-HA × TRAMP
double transgenic recipients were castrated 1 day prior to
adoptive transfer, CD4 cell proliferation was slightly enhanced
compared to intact counterparts; however, the CD4 cell prolif-
erative response was markedly diminished when castration
was performed 10 days prior to adoptive transfer (Figures 4A
and 4B). Castration did not completely eliminate antigen re-
cognition in ProHA × TRAMP mice—even 10 days after andro-
gen ablation, significantly greater CD4 T cell proliferation was
detected in ProHA × TRAMP animals than NT controls (Figure
4B). To assess whether the altered T cell response elicited by
androgen ablation was due to the removal of a direct immuno-
suppressive effect of androgen on T cell function (Roden et al.,
2004; Viselli et al., 1995), we adoptively transferred clonotypic
CD4 cells into either intact or castrated NT and C3-HA mice, or
intact or castrated NT mice infected with vacc-HA. As shown in
Figure 4D, division of HA-specific T cells was nearly identical
between castrated and intact animals for all three recipient
groups, suggesting that the effects of androgen ablation on
T cell recognition of the prostate gland (Figures 4A–4C) were
mediated by changes in the quantity and/or quality of antigen
recognition, rather than direct effects of androgens on T cell
function.
Androgen ablation mitigates systemic tolerance to
a prostate/prostate tumor-restricted antigen
These results suggested that androgen ablation in the setting
of prostate cancer eventually converts a tolerance-inducing
environment to one that is neutral. We therefore queried
whether this conversion would reverse the tolerization process
at the systemic level—permitting HA-specific T cells to expand
following vaccination. After allowing the adoptively transferred
clonotypic CD4 cells to remain in the various recipient groups
for a longer period (2 weeks), we assessed whether they could
undergo clonal expansion in prostate-non-draining LNs follow-
ing challenge with vacc-HA (Figure 5A). If NT recipients of 1 ×
105 naive clonotypic CD4 cells are challenged with vacc-HA,
the frequency of clonotypic CD4 cells expands to approxi-
mately 1% of the total lymphocyte population 6 days later
(without vacc-HA challenge this frequency is less than 0.1% in
NT mice, as well as in all other nonvaccinated control groups
[data not shown]). As a positive control for systemic tolerization
(i.e., impaired responsiveness to vaccination), naive clonotypic
CD4 cells parked for 2 weeks in C3-HA recipients exhibited a
greatly impaired ability to expand following vacc-HA challenge.
In Pro-HA single transgenic recipients, vacc-HA induced clo-
notypic CD4 cell expansion to a level that was slightly less than
NT controls (although not statistically different), consistent with
the minimal level of HA recognition that was occasionally ob-
served in Pro-HA single transgenic mice (Figure 3B). These
data further confirm that prostatic HA is mostly ignored in the
absence of tumorigenesis. In contrast, vacc-HA-induced clono-243
A R T I C L EFigure 4. Androgen ablation transiently increases presentation of prostate-epithelial antigen
Pro-HA and Pro-HA × TRAMP mice castrated at the indicated time points received adoptive transfers of Thy1.1+ CFSE-labeled naive clonotypic CD4 cells,
which were recovered from the prostate-draining periaortic LNs 6 days later.
A: Representative proliferative responses (i.e., CFSE dilutions) of clonotypic CD4 cells.
B: Scatter plot showing the effect of androgen ablation on clonotypic CD4 cell proliferation is presented as in Figure 3B.
C: Representative histogram plots of IFN-γ staining, with the percentage of cytokine-positive clonotypic CD4 cells, as well as the level of cytokine expression
on these positive cells (expressed as mean fluorescence [MF]) shown above and below the reference bar, respectively.
D: Comparison of CFSE dilution in clonotypic CD4 cells recovered from intact and castrated NT, vacc-HA-infected NT (vacc-HA), and C3-HA recipients.typic CD4 cell expansion was significantly reduced in Pro-
HA × TRAMP double transgenics. Since clonotypic CD4 cell
expansion was not impaired in TRAMP single transgenics,
these data indicate that tumorigenesis promotes systemic tol-
erization to HA, rather than inducing an antigen-nonspecific
immune suppression. Castration did not alter clonotypic CD4
cell expansion in NT or Pro-HA single transgenic recipients,
but was able to markedly mitigate the tolerogenic effect of tu-
morigenesis (Figure 5A), most likely due to the diminution of
tolerogenic antigen presentation over the 2 week period prior
to immunization with vacc-HA (Figure 4B). Intracellular staining
showed that clonotypic T cells from castrated Pro-HA × TRAMP
mice that had expanded following vacc-HA challenge pro-
duced IFN-γ in response to in vitro restimulation at levels com-244parable to control recipients, demonstrating that castration
truly mitigated tolerization (Figure 5B). In the above experi-
ments, T cells were adoptively transferred 24 hr after androgen
ablation. In clinical vaccination settings, prostate-specific T
cells would most likely be in circulation prior to either chemical or
surgical castration. To model this scenario, we adoptively trans-
ferred clonotypic CD4 cells to 12- to 14-week-old ProHA ×
TRAMP or NT mice 1 week prior to androgen ablation. Follow-
ing an additional week, the systemic immune response to HA
was assessed by challenge with vacc-HA as above. While the
frequency of prostate-specific T cells was not dramatically al-
tered by androgen ablation in these animals (data not shown),
their ability to produce IFN-γ was restored to levels observed
in NT control animals (Figure 5C). Interestingly, this mitigation ofCANCER CELL : MARCH 2005
A R T I C L EFigure 5. Tumorigenesis induces systemic tolerization to prostate-epithelial antigens, while castration mitigates this effect
A: Age-matched (6-month-old) NT (n = 10), NT castrated at day −1 (n = 6), C3-HA (n = 10), Pro-HA (n = 10), Pro-HA castrated at day −1 (n = 10), TRAMP
(n = 9), Pro-HA × TRAMP (n = 12), and Pro-HA × TRAMP castrated at day −1 (n = 6) Thy1.2+ recipients received adoptive transfers of 1 × 105 unlabeled
Thy1.1+ naive clonotypic CD4 cells, and 2 weeks later were challenged with 1 × 106 pfu of vacc-HA. Control NT mice received T cells, but not vacc-HA
(n = 7). Six days later, the frequency of clonotypic CD4 cells (identified as CD4+ and Thy1.1+) was measured in the prostate-non-draining axillary LNs.
Asterisks indicate groups that are significantly different (p < 0.05, unpaired two-tailed t test) from the NT control group.
B: Representative histogram plots of intracellular IFN-γ staining, with the percentage of cytokine-positive clonotypic CD4 cells shown.
C: 12- to 14-week-old NT or ProHA × TRAMP mice were adoptively transferred with 1 × 107 clonotypic CD4 cells 1 week prior to castration. After 1 additional
week, animals were challenged with vacc-HA and harvested 5 days later. Representative histograms of clonotypic CD4 cell intracellular IFN-γ staining
from irrelevant (systemic) LNs are shown.tolerance was not as pronounced in 18- to 22-week-old animals
with more advanced disease (data not shown). Taken together,
these data demonstrate that prostate tumorigenesis impairs
the systemic T cell response to prostate-specific vaccination
(i.e., promotes tolerance), while androgen ablation mitigates
this effect.
Discussion
Peripheral T cell tolerance can be mediated by a variety of
mechanisms. While active forms of tolerization such as dele-CANCER CELL : MARCH 2005tion (Jones et al., 1990) or functional inactivation (i.e., anergy)
(Mueller et al., 1989) are commonly observed, tolerance can
also be manifested passively, i.e., naive T cells may simply ig-
nore the presence of their cognate peripheral self-antigens
(Ohashi et al., 1991; Oldstone et al., 1991). In some cases, ig-
norance may result from low levels of self-antigen expression
(Kurts et al., 1998). In our Pro-HA system, ignorance most likely
occurs because HA is sequestered from the draining lymphat-
ics (Whitmore and Gittes, 1977) and, hence, tolerogenic APCs
(Adler et al., 1998; Higgins et al., 2002a, 2002b). Thus, both
prostate tumorigenesis and castration, which alter prostatic ar-245
A R T I C L Echitecture, significantly increase the level of cognate T cell rec-
ognition of a defined HA epitope that is presented in the drain-
ing LNs. Tumorigenesis might also increase T cell recognition
of HA by directly delivering HA to the draining LNs via meta-
static HA-expressing tumor cells or by increasing the overall
quantity of HA expression. Nonetheless, compromised seque-
stration likely plays a critical role, since the amount of HA re-
cognition in the prostate-draining LNs did not directly correlate
with either the size of the primary prostate tumors or with the
presence of enlarged draining LNs that would be indicative of
metastatic tumor (data not shown).
The functional consequence of the increased prostate-epi-
thelial antigen recognition by cognate T cells associated with
prostate tumorigenesis appears to be tolerance; cognate naive
CD4 cells undergo an abortive proliferative response and fail
to develop effector function (i.e., the ability to express Th1 or
Th2 cytokines). Even though tolerogenic presentation ap-
peared to be limited to the prostate-draining LNs, over time
there was a decrease in the ability of cognate CD4 cells to
undergo clonal expansion in response to vaccination, indicat-
ing that this presentation leads to systemic tolerization. This
probably occurs after all of the cognate CD4 cells have circu-
lated through the prostate-draining LN, as has been previously
described when self-antigen expression is limited to the pan-
creas (Morgan et al., 1999). In another transgenic system, the
development of insulinomas also enhances cross-presentation
of a tumor-associated antigen, but interestingly, the outcome
is not tolerance (Nguyen et al., 2002). Differences in the immu-
nological properties of transplantable tumors have also been
observed; in some cases these tumors are tolerogenic (Stave-
ley-O'Carroll et al., 1998; Bogen, 1996; Shrikant et al., 1999),
and in others immunogenic (Ochsenbein et al., 2001; Hanson
et al., 2000; Spiotto et al., 2002). These data underscore the
notion that different types of tumors are likely to have different
immunological properties. The tolerogenic nature of prostate
tumors might be conferred in part by their ability to produce
the immunosuppressive cytokine TGF-β (Barrack, 1997).
The observation that prostate tumorigenesis promotes toleri-
zation toward tumor-associated antigens has implications for
designing immunotherapy strategies to treat prostate cancer.
Given that tolerance does not appear to occur prior to tumori-
genesis, vaccines targeting antigens that are also expressed
on primary tumors might be effective when administered pro-
phylactically or at early stages of disease progression. This
would not necessarily be the case for other types of tumors
where the targeted tumor-associated antigens might promote
tolerance prior to tumorigenesis (Morgan et al., 1998; Hu et
al., 1993). At later stages of prostate tumor progression, when
tolerization becomes more apparent, vaccine efficacy would
likely decline. Consistent with this possibility, the ability of vac-
cines to impede disease progression in TRAMP mice declines
with age (Hurwitz et al., 2000), although factors other than tol-
erance (e.g., the establishment of an immunosuppressive tu-
mor microenvironment [Radoja et al., 2001]) might also contrib-
ute to this phenomenon.
Since androgen blockade is a standard therapy for prostate
cancer (Denmeade and Isaacs, 2002), understanding its effect
on tolerance is important in designing therapeutic strategies
that combine androgen blockade with vaccines. A recent study
has shown that prostate cancer patients undergoing androgen
ablation develop prostatic infiltration of T cells that appear to246exhibit a Th1 effector phenotype, suggesting that androgen ab-
lation induces T cell priming to prostatic antigens (Mercader et
al., 2001). We find that in the absence of tumorigenesis, andro-
gen ablation appears to induce prostate-specific naive CD4
cells to undergo tolerogenic differentiation. These CD4 cells
exhibit a CFSE-dilution profile indicative of an abortive prolifer-
ative response and also fail to develop the potential to express
effector cytokines. This result is consistent with studies show-
ing that cell death under noninfectious conditions promotes
tolerization (Hugues et al., 2002; Liu et al., 2002; Ferguson et
al., 2002) as well as the observation that castration enhances
prostatic expression of the immunosuppressive cytokine
TGF-β (Kyprianou and Isaacs, 1989). Nonetheless, androgen
blockade does not lead to systemic T cell tolerance, apparently
because the synchronous apoptosis of HA-expressing prostate
epithelia results in transient HA presentation in the draining
LNs that is insufficient in duration for all of the cognate CD4
cells to encounter HA.
Androgen ablation-induced prostate epithelial cell and tumor
cell apoptosis in Pro-HA × TRAMP double transgenic mice also
appears to lead to a transient but insignificant increase in the
level of HA recognition. Over time, HA recognition by cognate T
cells decreases, but even 10 days after castration, significantly
greater T cell recognition is observed in castrated Pro-HA ×
TRAMP mice than nontransgenic controls. Interestingly, sys-
temic tolerance to ProHA × TRAMP tumors is significantly miti-
gated around this time point. These data suggest that attenua-
tion of systemic tolerance is probably not mediated by the
complete elimination of tolerogenic antigen, but by either a re-
duction to levels below a threshold required to maintain nonre-
sponsiveness or possibly by other mechanisms affecting the
context of antigen recognition (Ramsdell and Fowlkes, 1992;
Pape et al., 1998).
Our data suggest that one approach to immunotherapy for
prostate cancer might be an adoptive immunotherapy strategy
(Yee et al., 1997) in which tumor-reactive effector T cells are
administered after androgen ablation. In this case, the de-
creased antigen burden mediated by castration (Figure 4B)
might prove particularly advantageous, since effector T cells
are highly susceptible to antigen-mediated tolerization (Higgins
et al., 2002a; Long et al., 2003; Mihalyo et al., 2004). For vac-
cine approaches, our data suggest that vaccination after an-
drogen ablation may augment efficacy (Figure 5C). It is impor-
tant to note that targeted vaccine approaches are dependent
upon sufficient expression of the target antigen by tumor cells.
While decreased target antigen expression secondary to an-
drogen ablation is a major concern, it should be noted that
most patients with prostate cancer who undergo androgen ab-
lation eventually relapse with a rising PSA, a canonical andro-
gen-regulated transcript (Gretzer and Partin, 2003; Prins,
2000). In TRAMP mice, a similar phenomena occurs: tumors
that progress in castrated animals express the SV40 large T
antigen, which is under the control of the androgen-regulated
probasin promoter (Eng et al., 1999), and in Pro-HA × TRAMP
mice, castration appears to reduce but not eliminate HA ex-
pression. Expression of these androgen-regulated genes in
castrate patients and TRAMP mice is most likely due in part to
alterations in either the expression or activity of the androgen
receptor, allowing activation in the absence of normal andro-
gen levels (Taplin and Balk, 2004; Chen et al., 2004; Edwards
et al., 2003; Hakimi et al., 1996; Zhao et al., 2000). Thus, pro-CANCER CELL : MARCH 2005
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targeted antigens, rendering them potentially susceptible to
immune eradication. Preliminary data in Pro-HA × TRAMP mice
support a sequential androgen-ablation / vaccination treat-
ment strategy (data not shown). However, extensive analyses
optimizing vaccine formulation and the timing of administration
relative to androgen ablation will be necessary to maximize the
clinical benefit of this combined-modality approach.
Experimental procedures
Mice
All mice were on the B10.D2 (H-2d) background. C3-HA transgenic mice
(founder line 142) that express influenza HA under the control of the rat
C3(1) promoter have been described (Adler et al., 1998, 2000). 6.5 (Kirberg
et al., 1994) and clone 4 (Morgan et al., 1996) TCR transgenic mice express
clonotypic TCRs that recognize either an I-Ed-restricted HA epitope
(110SFERFEIFPKE120) or a Kd-restricted HA epitope (542IYSTVASSL550),
respectively, and were both backcrossed to a Thy1.1 congenic B10.D2
background. TRAMP transgenic mice (Greenberg et al., 1995) on the
C57BL/6J background were backcrossed to the B10.D2 background.
Castration was performed as previously described (Eng et al., 1999).
The Pro-HA expression cassette was constructed by first PCR amplifying
the minimal Probasin promoter fragment (−426 bp to +28 bp) (Rennie et al.,
1993) from rat genomic DNA using the proofreading enzyme Pfu polymer-
ase (Stratagene, La Jolla, CA) and the primers 5#-ATCCTGAGCTCAAG
CTTCCAAAGTGCATTTAGC-3# and 5#-GAGGAGGATGACCCTCATCG-3#.
The purified product was digested with SacI and ligated into the SacI site
of pGem3 (Promega, Madison, WI). A secreted form of the HA gene derived
from the wild-type (wt) HA sequence of influenza virus A/PR/8/34 (Mount
Sinai strain) (Townsend et al., 1984) was constructed by PCR-based muta-
genesis using Pfu polymerase and the primers 5#-TTTCAAGATCTGCA
GGGGAAAATAAAAACAACC-3# and 5#-AGACCGGATCCTACAGTGAACTGG
CGACAGTTG-3#, which introduce a termination codon following amino acid
550. The 1.6 kb modified HA fragment was ligated downstream of the Pro-
basin promoter using StuI and BamHI sites. Finally, a 1 kb fragment contain-
ing the SV40 small T antigen 3#-untranslated region was PCR amplified
from the plasmid 3xHRE-3 (Adler et al., 1991) using Pfu polymerase and
the primers 5#-CGGGATCCATGTCGGCAGAATGC-3# and 5#-GAAGATCTG
ACACTATAGAATACAAGC-3#, and ligated downstream of HA using BamHI
and BglII sites. The entire 3.1 kb Pro-HA expression cassette was gel iso-
lated following digestion with HindIII and was microinjected into fertilized
B10.D2 embryos (performed at the Baylor College of Medicine transgenic
core facility). Transgenic progeny were identified by PCR analysis of DNA
extracted from tail biopsies using the primers 5#-GAATGGATAATAGTCAT
CATG-3# and 5#-GGTTTCCCAAGAGCCATC-3#.
Transient transfection and immunoprecipitation assay
COS-7 cells (1 × 105 plated in a 6-well plate 1 day earlier in DME media
containing 10% FCS) were transiently transfected with 5 g of mammalian
expression plasmids (i.e., pcDNA3) containing the indicated HA sequence
under the control of the viral CMV promoter using the DEAE-dextran
method as previously described (Adler et al., 1993). Forty-eight hours post-
transfection, the cells were given media containing DME without methio-
nine, 10% dialysed FCS, and 100 Ci [35S]methionine. After 1 hr, one group
of cells were harvested into 0.5 ml RIPA buffer (40 mM Tris [pH 8.0], 1%
deoxycholate, 150 mM NaCl, 1% NP40, 2 mM EDTA, 0.1% SDS, 1 mM
NaVO4, 120 M PMSF, 5 ug/ml aprotinin, 1 g/ml pepstatin, and 10 g/ml
leupeptin) (i.e., pulse), while the second group were washed, given media
containing an excess of cold methionine, and incubated an additional 3 hr
before harvesting into RIPA buffer (i.e., chase). Media samples were also
collected at the end of both the pulse and chase periods and mixed 1:1
with RIPA buffer. Subsequently, the cell lystates were spun at top speed in
a microcentrifuge at 4°C, and the supernatants precleared with 50 l protein
A sepharose (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 10 min at
4°C. The cleared supernatants were then incubated with the anti-HA mAb
H-18 for 2 hr at 4°C, immunoprecipitated with 50 l protein A Sepharose,
extracted with SDS-containing gel loading buffer, and run on SDS-PAGECANCER CELL : MARCH 2005gels containing 7.5% acrylamide. Dried gels were exposed to film for auto-
radiography.
Recombinant vaccinia viruses
A previously established protocol (Earl and Moss, 1993) was used to recom-
bine the HAs sequence into the TK gene of wild-type vaccinia virus using
the appropriate pSC11MCS1 vectors (in which the modified HA sequences
have been placed under the control of the early/late p7.5 promoter) in HuTK-
cells. Recombinant vaccinia expressing the wild-type HA sequence has pre-
viously been described (Staveley-O'Carroll et al., 1998). The recombinant
vaccinia viruses were amplified in HuTK- cells, purified over 36% sucrose,
and titered using HuTK− cells.
FACS staining of vaccinia-infected cells
P815 cells were infected in vitro with the indicated recombinant vaccinia
viruses at a multiplicity of infection (MOI) of 5 plaque forming units (pfu) per
cell. Sixteen hours later, the samples were split and either stained directly
with the HA-specific mAb H-18 followed by a PE-conjugated goat anti-
mouse Ig secondary stain (for surface HA staining) or fixed in PBS contain-
ing 4% formaldehyde for 5 min at 37°, followed be permeabilization in FACS
buffer (PBS containing 2% calf serum and 0.1% azide) supplemented with
0.25% Saponin, and then staining with H-18 and PE-conjugated goat anti-
mouse Ig (for intracellular HA staining).
Quantitative RT-PCR
RNA was extracted from the indicated tissues using the RNeasy kit (Qiagen,
Chatsworth, CA) and DNase treated. cDNA was transcribed using the Su-
perScript II system (Life Technologies, Rockville, MD), and PCR reactions
were run in triplicate wells in an ABI 7700 instrument (PE Applied Biosys-
tems, Foster City, CA). In each reaction well, 18S rRNA-specific primers and
VIC-labeled probe (Applied Biosystems) were run concurrently to normalize
input cDNA. Relative HA expression was calculated using the delta-delta
CT method (18), with RNA from C3-HA prostate serving as a standard (set
at 100). The HA-specific primers were 5#-CGCCGGATGGCTCTTG-3# (for-
ward) and 5#-ACAATGTAGGACCATGATCTCACTG-3# (reverse). The HA-
specific probe was 5#-FAM-AAACCCAGAATGCGACCCACTGCTT-TAMRA-
3#. No amplification was detected in the absence of template.
Adoptive transfers and flow cytometry
Adoptive transfers of Thy1.1+ naive clonotypic TCR transgenic T cells into
male Thy1.2+ recipients and intracellular cytokine staining of CFSE-labeled
Thy1.1+ clonotypic CD4 cells following in vitro restimulation with HA peptide
were performed as previously described (Higgins et al., 2002a, 2002b; Long
et al., 2003), except that restimulation was performed with 2 × 106 LN cells
in 200 l CTL media per well in v-bottom 96-well plates.
Prostatic HA expression bioassay
Whole prostates were homogenized in 500 l PBS using an Omni TH hand-
held homogenizer (Omni International, Warrenton, VA), and 100 l of the
homogenates (containing approximately 60 g protein) were injected into
the footpads of NT mice that had received adoptive transfers of naive 6.5
clonotypic CD4 cells 1 day earlier. Five days later, single-cell suspensions
prepared from the draining popliteal LNs were analyzed by FACS to deter-
mine CD44 expression on the clonotypic CD4 cells as previously described
(Adler et al., 1998, 2000; Higgins et al., 2002b).
Histological analysis of prostate-infiltrating clonotypic CD8 cells
Two weeks following adoptive transfer of Thy1.1+ clone 4 clonotypic CD8
cells and vacc-HA inoculation (1 × 107 pfu administered i.p.), dorsal pros-
tate lobes were removed from the indicated Thy1.2+ recipients, embedded
in Tissue-Tek OCT freezing compound (Sakura Kinetek, Torrance, CA), and
frozen in liquid N2. Four micron sections were cut using a cryostat, placed
onto poly-lysine-coated slides, air-dried for 1 hr, fixed in acetone for 5 min
at 4°C, and air dried for 10 min at RT. All subsequent steps were performed
at RT. Dried sections were soaked in PBS for 10 min, incubated with Per-
oxo-Block (Zymed, South San Francisco, CA) for 45 s, washed 3× with
PBS, incubated sequentially with avidin and biotin block (Vector Laborato-
ries, Burlingame, CA) for 15 min with an intervening wash (3× with PBS),
blocked for 10 min in binding buffer (PBS + 5% FCS), incubated with biotin-
conjugated anti-Thy1.1 (BD Pharmingen, San Diego, CA) (0.5 g/ml in bind-247
A R T I C L Eing buffer) for 30 min to mark the primed clonotypic CD8 cells, developed
with streptavidin-peroxidase followed by AEC (producing a red stain), and
then counterstained with hemotoxylin prior to mounting (using the Histo-
mouse-SP Kit as per the manufacturers instructions [Zymed]).
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